Davis Polk advised J.P. Morgan and BofA Merrill Lynch as representatives of the several underwriters on a $97.8 million SEC-registered offering of common stock of Esperion Therapeutics, Inc., which includes the full exercise of the underwriters’ option to purchase additional shares. The common stock is listed on the NASDAQ Global Market under the symbol “ESPR.”  

Esperion Therapeutics, based in Ann Arbor, Michigan, is an emerging pharmaceutical company focused on developing and commercializing first in-class, oral, low-density lipoprotein cholesterol (LDL-cholestrol) lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers.

The Davis Polk corporate team included partner Bruce K. Dallas and associate Jeffrey Hedrick. Associate Fiona Finlay-Hunt provided intellectual property advice. Partner Rachel D. Kleinberg and associate Neetin Gulati provided tax advice. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Menlo Park and New York offices.